Levetiracetam attenuates spontaneous spike-and-wave discharges in DBA/2J mice.
Recent evidence highlights levetiracetam (LEV) as an advantageous treatment of absence epilepsy (AE). Thus, we investigated the effects of this drug in DBA/2J mice, a murine model of AE. Similarly to ethosuximide (200 mg/kg, intraperitoneal, i.p.) and sodium valproate (250 mg/kg, i.p.), two classic antiabsence agents, LEV (50-200 mg/kg, i.p.) reduced the occurrence of spike-and-wave discharges, AE's typical electroencephalographic patterns. Our results confirm LEV's efficacy in AE treatment.
Marrosu
Francesco
F
Department of Neurological and Cardiovascular Sciences, University of Cagliari, Policlinico Universitario, S.S. 554 Km 4.500, 09042 Monserrato (CA), Italy. marrosu@unica.it
Bortolato
Marco
M
Frau
Roberto
R
Orrù
Marco
M
Puligheddu
Monica
M
Fà
Mauro
M
Muroni
Antonella
A
Tuveri
Antonella
A
Mereu
Giampaolo
G
D000818:Animals; D000927:Anticonvulsants / Q000008:administration & dosage / Q000494:pharmacology*; D004569:Electroencephalography / Q000187:drug effects*; D004832:Epilepsy, Absence / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D005013:Ethosuximide / Q000008:administration & dosage / Q000627:therapeutic use; D007274:Injections, Intraperitoneal; D000077287:Levetiracetam; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D010889:Piracetam / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D014635:Valproic Acid / Q000008:administration & dosage / Q000627:therapeutic use
D000927:Anticonvulsants; D000077287:Levetiracetam; D005013:Ethosuximide; D014635:Valproic Acid; D010889:Piracetam